|1.||Cendán, Cruz M: 2 articles (07/2009 - 11/2005)|
|2.||Baeyens, José M: 2 articles (07/2009 - 11/2005)|
|3.||Pouzet, B: 1 article (05/2013)|
|4.||Galley, G: 1 article (05/2013)|
|5.||Risterucci, C: 1 article (05/2013)|
|6.||Wallace, T L: 1 article (05/2013)|
|7.||Buchy, D: 1 article (05/2013)|
|8.||Mory, R: 1 article (05/2013)|
|9.||Moreau, J-L: 1 article (05/2013)|
|10.||Revel, F G: 1 article (05/2013)|
|1.||Schizophrenia (Dementia Praecox)
09/01/2000 - "Comment on 'reduced haloperidol does not interfere with antipsychotic activity of halperidol in the treatment of acute schizophrenia'."
01/01/1990 - "Reduced haloperidol plasma concentration and clinical response in acute exacerbations of schizophrenia."
01/01/1989 - "Hydroxyhaloperidol and clinical outcome in schizophrenia."
07/01/1999 - "The aim of this study was to investigate the effect of reduced haloperidol, the main metabolite of the antipsychotic drug haloperidol, on psychopathology improvement and extrapyramidal adverse effects in acute schizophrenia. "
07/01/1999 - "It is concluded that serum concentrations of reduced haloperidol are of minor value for the interpretation of data of therapeutic drug monitoring of haloperidol in patients with acute schizophrenia. "
|2.||Dystonia (Limb Dystonia)
07/03/1995 - "Injection of haloperidol and reduced haloperidol 1, 3 and 10 days earlier exacerbated the dystonic response by decreasing the latency to maximal dystonia and increasing the duration of the response at each dose tested compared with saline-treated animals. "
01/01/1987 - "Pargyline caused no changes in baseline behaviors, but significantly reduced haloperidol-induced acute dystonia (AD) (-67%, P less than 0.002) and parkinsonism (-56%, P less than 0.005). "
07/03/1995 - "Haloperidol and reduced haloperidol-induced exacerbation of the dystonia produced by the kappa opioid U50,488H in guinea-pigs is associated with inhibition of sigma binding sites: behavioural and autoradiographical studies."
09/30/2011 - "THIM-exposed rats also manifested reduced haloperidol-induced catalepsy, accompanied by a marked decline in the density of striatal D₂ receptors, measured by immunohistochemical staining, suggesting alterations to the brain dopaminergic system. "
07/01/2004 - "Furthermore, antagonizing the A(2A) receptor (R) reduced haloperidol induced catalepsy. "
01/01/1997 - "The motor effects of all the reduced haloperidol and bromoperidol metabolites were evaluated by the mouse catalepsy test. "
01/01/2002 - "The non-competitive antagonist of receptor subtype 5 (mGluR5), MPEP (1.0-10 mg/kg ip), or the agonist of group II mGluRs, LY354,740 (5-10 mg/kg ip), reduced haloperidol-induced muscle rigidity and catalepsy. "
10/01/2008 - "SCH 412348 (10 mg/kg) and caffeine (10 mg/kg) significantly reduced haloperidol-induced catalepsy. "
07/01/2009 - "Subcutaneous administration of haloperidol or its metabolites I or II (reduced haloperidol) dose-dependently reversed capsaicin-induced (1 microg, intraplantar) mechanical hypersensitivity of the hind paw (stimulated with a nonpainful, 0.5-g force, punctate stimulus). "
07/25/1980 - "These results clearly demonstrate that amantadine greatly reduced haloperidol-induced striatal dopamine receptor hypersensitivity and support the hypothesis that amantadine given concurrently with neuroleptic agents might serve to prevent the development of human tardive dyskinesia."
|5.||Body Weight (Weight, Body)
06/01/2000 - "The Css of haloperidol and reduced haloperidol were measured in duplicate by high performance liquid chromatographic method, and were corrected to the mean body weight. "
05/01/2013 - "TAAR1 agonists do not induce catalepsy or weight gain; RO5263397 even reduced haloperidol-induced catalepsy and prevented olanzapine from increasing body weight and fat accumulation. "
|2.||(trans)-Isomer 3,4- Dichloro- N- methyl- N- (2- (1- pyrrolidinyl)- cyclohexyl)- benzeneacetamide
|3.||Risperidone (Risperdal Consta)
|4.||Cytochrome P-450 CYP2D6 (CYP2D6)
|5.||Cytochrome P-450 CYP1A2 (CYP1A2)
|6.||sigma Receptors (sigma Receptor)
|8.||N-Methyl-D-Aspartate Receptors (NMDA Receptors)
|9.||1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
|10.||Antipsychotic Agents (Antipsychotics)